Natural Protein May Provide Benefits against Stroke

Studies found administering Cryab to animals 12 hours after stroke induction led to significantly reduced stroke volume and lower levels of inflammatory cytokines.

Scientists suggest that treating stoke patients with an endogenous immunomodulatory neuroprotectant protein, αB-crystallin (Cryab), could help limit brain damage even if first administered 12 hours after the onset of stroke.

Studies by a Stanford University School of Medicine team in a mouse model of stroke found that administering Cryab to animals 12 hours after stroke induction led to significantly reduced stroke volume and lower levels of inflammatory cytokines associated with stroke pathology than untreated mice. Conversely, animals in which the Cryab gene had been knocked out demonstrated increased lesion size and diminished neurologic function after stroke than wild-type mice.

The research team, led